Halozyme Therapeutics has withdrawn its proposal to buy Evotec SE for 2 billion euros ($2.09 billion) as the German drug developer was unwilling to engage in discussions, the U.S. firm said on Friday.

Triton Wealth Management PLLC increased its holdings in Microsoft Co. (NASDAQ:MSFT – Free Report) by 9.0% in the third ...

A six-bedroom, six-bath house at 134 Shore Drive West in New Seabury sold for $8.75 million on Oct. 30, breaking a price ...

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

Stryker Corporation SYK has announced the launch of the next generation of SurgiCount+ within its sponge management portfolio ...

Finland’s Cargotec has signed an agreement to sell its MacGregor business area to funds managed by private equity firm Triton ...

market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on EVO: Evotec price target lowered to EUR 11.60 from EUR 12 at RBC Capital Evotec rallies ...

Almost half of all Triton Mid-Market investments made since inception have been carve-outs. Ilkka Tuominen, investment ...

Each year, UC San Diego joins hundreds of institutions worldwide to celebrate IEW, a joint initiative of the U.S. Departments ...

Mitsubishi Motors Corporation announced that the all-new Triton one-ton pickup truck has won the special award at the RJC Car ...